



Steven Geringer Data Science Solutions Architect IBM Analytics <u>steve.geringer@ibm.com</u>





2



### About Me:

- I Love Algorithms
- Once owned CobaltAI.com (2002-2005)
- Kaggle "Competitions Expert" (Two Silver Medals, 2014-2015)





## Agenda

3

- The Future of Data Science
- Analytics Portfolio Overview
- Data Science Experience Local Architecture
- Crash Course on Machine Learning
- DSXL Demo





© 2018 IBM Corporation. Author: Steven Geringer, Data Science Solutions Architect. Permission is granted to use or distribute this unmodified image, provided that this copyright remains intact.

# **Analytics Maturity Curve**





Capabilities



## **Picture the Future of Data Science**

### Trends

- Data Is Growing Exponentially
- Data Science is Growing Linearly
  - Platform Market: CAGR 36.5%
  - Personnel: CAGR 28%
- Massive Expansion in:
  - Open Source
  - Data Science Use Cases
  - New Algorithms
  - Techniques
  - Data Types
- Microservices Replacing Monolithic Software

## Challenges and Pain Points

- Skill Shortages
- Job Hopping
- Low Productivity
- Disjointed Tools
- Data Integrity
- Cannot find or access to required data
- Organizations not using Insights from DS
- "Data Science Disillusionment"

Sources:

https://www.forbes.com/sites/louiscolumbus/2017/05/13/ibm-predicts-demand-for-data-scientists-will-soar-28-by-2020/#4a68516a7e3b https://www.reuters.com/brandfeatures/venture-capital/article?id=5670

<sup>© 2018</sup> IBM Corporation. Author: Steven Geringer, Data Science Solutions Architect. Permission is granted to use or distribute this unmodified image, provided that this copyright remains intact

BM Analytics

### **Forrester Research - December 2016**

Data Science Platforms Lead to Better Data Science Results

A Forrester Consulting December 2016 Thought Leadership Paper Commissioned By DataScience **Data Science Platforms** Help Companies Turn **Data Into Business Value** 

FORRESTER

Author: Steven Geringer, Data Science Solutions Architect. Permission is granted to use or distribute this unmodified image, provided that this copyright remains intact

## **IBM's Comprehensive Platform for Your Information Architecture**



### **Data Science & Business Analytics**

8

9



### **Benefits of Microservices vs. Monolithic Software**



Scalability

- Agility
  - Increase autonomy of teams
  - Enables continuous delivery
- Manageability
- Encapsulation
- Innovation
  - Polyglot Development
- Quality
  - Better fault isolation
- Availability

Netflix Microservice Architecture

Source: https://www.infoq.com/presentations/netflix-chaos-microservices

10

## **Data Science Is a Team Sport**





## **Analytics Portfolio Overview**

## **IBM Cognos Analytics (Descriptive)**

- Integrated solution for managed reporting and business user self-service
- Designed for ease of use with a graduated user experience that enables analytic consumers to progress to access and model data, and create visual dashboards <sup>1</sup>/<sub>2</sub> and stories on their own
- Smarter self service uses built in intelligence to guide data modeling and authoring based on intent
- Proven governed solution for performance, security and scalability





13

## **IBM Planning Analytics (Descriptive)**

- Planning, budgeting, and forecasting for strategic, financial and operational needs
- Single platform for business planners to load data, model their business across multiple dimensions, and manage results in real-time
- Automates manual, disconnected spreadsheet-based planning with a more powerful and collaborative approach and customizable planning workspace







## **IBM Watson Explorer (Diagnostic)**

- Unlocks the Hidden Power of the your Unstructured Data
- Text Analytics, Natural Language Processing
- Gain deeper insights advanced content analytics
- Ability to handle all types of data
- Expert identification and location
- Team Collaboration
- Natural language query
- API Accessible

New Adaption with the Concept United Workshop Operation & Discovery of the Strict Workshop Operation & Discovery Operation & Discover	exact with state Concept Delevant of Deleva	0 169.45.196.45:839	13/ui/analyt	lics/AlchemyConceptDiscovery		C Q S	Search 🗘 🖻 🛡 🏦 🖡 🍒 🖸
Fact Navigation     Fact Navigation     Fact Navigation     Fact Navigation     Fact Strevel S     Section      Terms     Prace Operator: AND     Prace Operator: AND     Prace     Prace     Prace Operator: AND     Prace	Paret Navigation <ul> <li>err</li> <li>Deviations</li> <li>France Constituent ©</li> <li>Sertiment Expression</li> <li>Model</li> <li>Walkes</li> <li>Frequency</li> <li>Correlation</li> <li>Values</li> <li>Frequency</li> <li>Correlation</li> <li>Values</li> <li>Sertiment Expression</li> <li>Model</li> <li>Values</li> <li>Frequency</li> <li>Correlation</li> <li>Values</li> <li>Values</li> <li>Frequency</li> <li>Correlation</li> <li>Values</li> <li>Sertiment Expression</li> <li>Model</li> <li>Values</li> <li>Frequency</li> <li>Correlation</li> <li>Values</li> <li>Service Value</li> <li>Values</li> <li>Frequency</li> <li>Correlation</li> <li>Values</li> <li>Service Value</li> <li>Values</li> <li>Service Value</li></ul>	News Analysis with Conce	pt Discove	ary powered by Alchemy	word::/ <b>'MeSH'/'Level 5'/'Se</b> 10362/44603 re	sults matched 🙆 🔾 👁 Show ad	Collection: PubMed-PDF - Q guest -
	Vertication       Vertication       Rends       Rends       Tends       Rends       Connections         Part of Speech       Speec       No       No       Rends       Feeders       Rends       Rends <td< th=""><th></th><th></th><th>,,,,,,, .</th><th></th><th></th><th></th></td<>			,,,,,,, .			
Parter       Seve:       Notes       Operator:       AND	Serve:       AND       Control       Filter       Results regrander         Parted Societion       Process Constituent ©	· Facet Navigation		<ul> <li>tent Control Control</li> <li>Deviations</li> <li>Trends</li> </ul>	Facet Pairs Connections	B Dashboard	
Part of Speech ●     Partsac Construct ●     Par	Pard Speech © Parase Constitutet ● Sectioner Expression MoSH Level 0 Level 0 Level 3 Level 4 Montailty 10042 Probability Proba	Filter		Show: Values * Operator: AND *	(b) (b) (c) Filter:	B. B.	Results 1-50 of 10362 Contextual Views * Action
Protect Construction     Sections     Sections     Sections     Sections     Sections     Values     Proceeding     Values     Value	Immas       Prequency       Correlation       Correlation       Correlation         MoSH       Mortally       19982       Correlation       Correlation         Level 0       Mostally       19982       Correlation       Correlation         Level 1       Wild Staticion       19982       Correlation       Correlation         Level 2       Sepsis       19982       Correlation	Part of Speech					I 2 3 4 5 10 ► Sort by: date Descending ▼ Results per page: 10 25
Values       Prequency       Correlation         W6H       Modify       10062       17         Level 0       Modify       10062       17         Level 1       Vala Statistica       10062       17         Level 3       Sepsis       10062       17         Level 4       Modify       10062       17         Level 5       Modify       10062       17         Level 5       Modify       7663       1         Level 6       Probability       7663       1         Level 8       Modify       7663       1         Level 10       Wdis       5660       10         Level 11       Granucoptability       7663       1         Level 12       Modify       7663       1         Level 13       Modify       7663       1         Level 14       Modify       7663       1         Level 13       Modify       7663       1         Level 14       Modify       7663       1         Level 15       Granucoptability       7663       1         Level 14       Modify       7663       1       1         Level 14       Modify	Values     Prequency     Correlation       MoSH     Mortaly     100/02     12       Level 0     Mortaly     100/02     12       Level 1     Value faitaficion     100/02     12       Level 3     Mornalih     8464     1       Level 4     Mortality     70/03     10       Level 4     Mornalih     8464     1       Level 5     Mortality     70/03     10       Level 6     Mortality     70/03     1       Level 7     Rek     70/03     1       Level 8     Indexec     96/06     1       Level 14     Indexec     96/06     10       Level 14     Genes     86/06     10       Level 12     Immunophabulins     84/06     10       Level 14     Immunophabulins     84/06     10       Level 12     Immunophabulins     84/06     10       Level 14     Immunophabulins     84/06     10       Level 14     Immunophabulins     84/06     10       Level 12     Immunophabulins     84/06     10       Level 14     Immunophabulins     84/06     10       Level 14     Immunophabulins     84/06     10       Level 14     Immun	Phrase Constituent					PMC5639490.pdf
Level 0         Mortality         10982         12           Level 1         Viol 8 distriction         19982         10           Level 2         Expelia         19982         10           Level 3         Expelia         19982         10           Level 4         Mammals         46464         1         10           Level 4         Mammals         46464         1         10         00.00.00 //10.0	Level 1     Mortality     10362     1       Level 1     Will Statics     10362     1       Level 2     Sepsis     10362     1       Level 3     Sepsis     10362     1       Level 4     Mortality     10362     1       Level 5     Pobability     1983     1       Level 4     Mortality     10862     1       Level 4     Pobability     1983     1       Level 5     Pobability     1086     100       Level 4     Mortality     1086     100       Level 5     Pobability     100     100       Level 10     Genes     809     10       Level 11     Immunglobulins     4116     1       Level 12     Immunglobulins     4116     1       Level 13     Immunglobulins     4116     1       Level 14     Immunglobulins     4116     1       Level 13     Genuloging fee     4433     1       Level 14     Immunglobulins     4116	<ul> <li>MeSH</li> </ul>	0	Values	Frequency + Cor	relation	Ovi 12, 2017, 1:00:00 DM
Level 1 Vada Statistics Vada S	Level 1 Level 3 Level 3 Level 4 Level 5 Level 5 Level 6 Probabily Pr	Level 0		Mortality	10382	17	
Level 2 Level 3 Level 4 Level 4 Level 5 Level 6 Level 7 Level 6 Level 7 Level 6 Level 7 Level 8 Lovel 4 Level 6 Level 7 Level 8 Lovel 4 Level 6 Level 7 Level 10 Copyright Level 12 Level 10 Level 12 Level 14 Leve	Level 2         Immunos         Level 3         Compliance	Level 1		Vital Statistics	10982		mortality from SMA is lower than that from CM (1-5%) CM was defined as (
Level 3         unreal         Lower 4         Mammalia         Geldes         1           Level 4         Mammalia         Geldes         1         -	Level 3     Versa     Team     Image: Constraint of the second	Level 2		Sanaia	10302		coma (Blantyre coma score [BCS] ≤ 2), (2) P. falcip-arum on blood smear, and ( no other known cause
Level 4         merrams         area         1           Level 5         Morbidly         7989         D           Level 6         Probability         7983         D           Level 7         Probability         7983         D           Level 8         Probability         7983         D           Level 7         Probability         7983         D           Level 8         Indiance         5969         D           Level 9         Indiance         5969         D           Level 10         Genes         6996         D           Level 12         Immunopbulins         4716         D           Level 12         Immunopbulins         4718         D           Level 14         Indiances         5696         D           Level 12         Immunopbulins         4718         D           Level 13         Granulocytes         6483         D           Level 14         Indiances         5696         D           Level 13         Granulocytes         6483         D           Level 14         Indiances         5696         D           Level 14         Indindiances         6696         D <td>Level 4     memma     areas     1       Level 5     Motiday     7090     32:       Level 6     Pobability     7090     32:       Level 7     Risk     7083     2       Level 8     Indence     5000     10:       Level 9     Motiday     5000     10:       Level 10     Wis     5000     10:       Level 12     Immunogloulins     37:16     30:       Level 12     Immunogloulins     37:16     30:       Level 14     Granulocytes     4433     30:       Level 14     Indirectual Property     4255     2:1       Level 14     Convingt 10:     51:00:     10:       Cotyright     4245     2:1     10:</td> <td>Level 3</td> <td></td> <td></td> <td>10362</td> <td></td> <td>and RNA isolation Whole blood was collected at enrollment in of additive per</td>	Level 4     memma     areas     1       Level 5     Motiday     7090     32:       Level 6     Pobability     7090     32:       Level 7     Risk     7083     2       Level 8     Indence     5000     10:       Level 9     Motiday     5000     10:       Level 10     Wis     5000     10:       Level 12     Immunogloulins     37:16     30:       Level 12     Immunogloulins     37:16     30:       Level 14     Granulocytes     4433     30:       Level 14     Indirectual Property     4255     2:1       Level 14     Convingt 10:     51:00:     10:       Cotyright     4245     2:1     10:	Level 3			10362		and RNA isolation Whole blood was collected at enrollment in of additive per
Level 5     Morisory     Zevel 3       Level 6     Probability     Zevel 3       Level 7     Pisak     Zevel 3       Level 8     Incidence     Segio       Level 9     Wills     Segio       Level 10     Wills     Segio       Level 11     Genes     Segio       Level 12     Immodphilins     3/15       Level 13     Granucopbulnis     3/15       Level 14     Indiacteux Pippty     Segio 1.0       Level 14     Indiacteux Pippty     Segio 1.1       Level 13     Granucoptes     Segio 1.0       Level 14     Indiacteux Pippty     Segio 1.1       Level 12     Immodphilins     3/15       Level 13     Granucoptes     Segio 1.1       Level 14     Indiacteux Pippty     Segio 1.1       DogBank     Copyright     42455	Level 5     morisory     revel     P       Level 6     Pobability     7083     1       Level 7     Rak     7083     2       Level 8     Norsion with Status of and space to Institute to Brainfer Index on PHRP-2 are to an index to Brainfer Index on PHRP-2 are to an index to Brainfer Index on PHRP-2 are to an index of the space	Level 4 Level 5 Level 6 Lovel 7 Level 8		Marriens	0464		the PAXgene Blood RNA Kit ( by this method were further cultured on blood
Level 0         Productify         Prod         1           Level 7         • Risk         7633         2           Level 8         • Indence         8680         2           Level 9         • Indence         8680         2           Level 9         • Wis         6890         2           Level 9         • Wis         6890         2           Level 10         Genes         6990         2           Level 12         • Immunoglobulins         8716         2           Level 13         Granuloxyles         6493         2           Level 14         Indencicyles         6493         2           herdelse los 0,	Level of Level 7         Processity         Processity         Processity         Processity         Description         Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>			Morbiaity	7989		or chocolate agar to further rule out bacterial infection. PfHRP-2
Level 8         Risk         7683         32         Bits, 65% for children without Bottering P = 0.88). Moreover, group A           Level 9         Indence         5660         562         Indence         For an and the set of the s	Level 8         Pick         Pice		0	Probability	7963	.1	not differ significantly among the 1/7, 14.3%, for children with bacteremia vs.
Incidence         Segin         Ipp           Level 9         Wdis         Segin         Ipp           Level 10         Genes         Segin         Ipp           Level 11         Genes         Segin         Ipp           Level 12         Immunoglobulins         3/16         Ipp           Level 13         Granuloydes         Segin         Ipp           Level 14         Indiscut Poppty         Segin         Ipp           hindiscut Poppty         Segin         Ipp         Ipp           Level 13         Granuloydes         Segin         Ipp         Ipp           Level 14         Indiscut Poppty         Segin         Ipp	Level 9         Incidence         SBB         IP         Increases the risk of inciding's SM, such as increases [46], could be contributing to SM, such as increases [46], could be contreses [46], could be contreses [46], could be contrese		< C	Risk	7683	2	8/85, 8.5% for children without Decletering, P = 0.68). Moreover, group A
Level 10         Wis         5520         1.0           Level 11         Genes         4996         10           Level 12         Immunoglobulins         4716         10           Level 13         Genulocytes         4493         10           Level 14         Intellectual Property         4255         1.1           > DrugBank         Copyright         4245         1.1	Level 10         Wils         9500         1.0           Level 11         Genes         48/96         10           Level 12         Immunoglobulins         47/16         10           Level 13         Genulocytes         44/33         10           Level 14         Intelectual Property         4255         1.1           DugBark         Copyright         4245         1.1	Level 9	0	Incidence	5626	12	increases the risk of mortality in SM, such as <b>bacteremia</b> [46], could be
Level 11         Genes         den96         III           Level 12         Immunopbulins         4716         III         Oct 12, 2017, 10:00 PM           Level 13         Granulocytes         4493         III	Level 11         Cons         db96         Immunoplebulins         PMC5439770.pdf           Level 12         Immunoplebulins         4716         Immunoplebulins         Constantiants           Level 13         Connolocytes         H453         Immunoplebulins         Constantiants           Level 14         Initiatiestual Property         4255         1         Code Statistics were missing laboratory values (hemoglobin unbit topic antibit)           DagBank         Copyright         4245         1         Code Statistics and those stat	Level 10	0	Wills	5576	1.0	contributing to death in those children with CM
Level 12         Immunoglabulins         4715         Computing           Level 13         Granulogdes         4493         Computing         Computing<	Level 12         Immunoglobulins         # 16         M           Level 13         Granulog/des         # 4453         M           Level 14         Indirectual Property         # 4255         1           Dagtlank         Copyright         # 2455         1	Level 11	0	Genes	4896	13	📔 🚡 PMC5639770.pdf
Level 13         Granulocytes         4493         Image: Constraint of the constraint o	Level 13         Granulocytes         #4493	Level 12	0	Immunoglobulins	4716	1.3	Oct 12, 2017, 1:00:00 PM
Level 14         Intellectual Property         4255         1         university and units and un	Level 14         Intellectual Property         4255         1         university tom	Level 13	0	Granulocytes	4493	1.8	Approximately 2% of patients were missing laboratory values (hemoglobin,
Copyright 4245     Copyright 4245     Copyright 4245     Copyright 4245	Linggeank Copyright Copyright 4245 1.1 0.055 Meningtis 0 (0) 160 (5) 0.18 Collaboration 51 (100) 3061 (00) 0.17 Empyr	Level 14	0	Intellectual Property	4255	1.1	white prood cell count, or pratelets) from
0 (0.0) 2 10 (0.7) 0.01 Cellulitos 2 (3 0 (1.0) 17.8 (0.4) 0.01 Plateletes *	a (a.o) £ i a (a) (1.0) 17.6 (0.4) 0.51 Plateete k 10 97	<ul> <li>DrugBank</li> </ul>	1	Copyright	4245	1.1	0.055 Meningitis 0 (0) 160 (5) 0.18 Bacterentii 51 (100) 3061 (96) 0.17 Empyer 5 (9 8) 215 (6 7) 0.81 Cellulitis 2 (3 0 (10) 17 8 (0.4) 0.61 Pertodets x 10 0.8
Neutrophils 251.3 (25.9) 213.6 (2.1) 0.03 In hospital mortality 6 (11.8) 480 (15) 0.52	Neutrophils 4180 1.7 251.3 (25.9) 213.6 (2.1) 0.03 In hospital mortality 6 (11.8) 480 (15) 0.52 A		1	Neutrophils	4180	1.7	251.3 (25.9) 213.6 (2.1) 0.03 In hospital mortality 6 (11.8) 480 (15) 0.52 A
Risk Factors 2004	damaged joint is more likely to become infected in patients with sectores the		-	Risk Factors	3964	13	damaged joint is more likely to become infected in patients with sectoremia that
Neutrophils 251.3 (25.9) 213.6 (2.1) 0.03 In hospital mortality 6 (11.8) 480 (15)	Neutrophils 4180 17 251.3 (25.9) 213.6 (2.1) 0.03 in hospital mortality 6 (11.8) 480 (15)	Level 11 Level 12 Level 13 Level 14 > DrugBank		Cenes Immoglobulins Granulocytes Intellectual Property Copyright Neutrophis	4996 4716 4493 4255 4245 4190	10 18 18 14 14 14 14	Cot 12, 2017, 10:000 PM



### Watson Explorer (cont'd)

*Extracts information* from text comprehensively so text data can be handled as structured data *Computes statistical* scores such as frequency and correlation of extracted keywords

*Visually displays* scores so users can understand characteristics of information in text data

Key information is

00440

identified and categorized through annotation

PC 143 (Hunter) 15 June 2006 23:47 Suspect identified himself as John Setsuko. Matched description given by night club doorman (IC1, Male, Ag 22-24 yrs, blue Everton shirt). Stopped whilst driving White Ford Mondeo, W563 WDL. Address given as 22 East Dene

Ridge, Copdock, Ipswich. Searched at scene and found in

possession of 1oz Cannabis Resin and lockable pocket knife.

CUTERIUM PROPER	PG 145
Arrest_Date_Time	15/06/2006 : 23:47
Suspect_Forename	John
Suspect_Surname	Setsuko
Suspect_VRN	W563WDL
Suspect_Vehicle_Color	White
Suspect_Vehicle_Make	Ford Mondeo
Suspect_Addr_Street	22 East Dene Ridge
Suspect_Addr_Town	lpswich
Evidence_1_Description	1 oz Cannabis Resin
Classification	Drug possession

Arresting Officer

**Content mining:** Annotations are stored in a text index. Statistical scores (correlation, trends, etc.) are computed and visualized



#### 2D Map Analysis



© 2018 IBM Corporation. Author: Steven Geringer, Data Science Solutions Architect. Permission is granted to use or distribute this unmodified image, provided that this copyright remains intact.

## **IBM Data Science Experience (Predictive)**

- Enterprise Grade Data Science platform
- Team Collaboration Features
- Curated Open Source Packages
- Multiple IDEs
  - Jupyter, Zeppelin, H2O Flow, RStudio
- GPU Support
- Scalable Microservices Cloud Architecture
- Community: tutorials, examples and experts
- Model Management and Deployment
- Integrates IBM's Data Science Portfolio





### **Enterprise Grade Data Science Platform**

## **IBM SPSS Modeler (Predictive)**

- "Drag and Drop Data Science"
- Accelerate time to value from data discovery to machine learning and application development
- Powerful single environment for data, algorithms, model development and machine learning
- Out-of-box industry leading algorithms and capabilities
- Mission-critical deployment and scale

#### SPSS Modeler on Desktop



### SPSS Modeler in DSXL



## **IBM Decision Optimization (Prescriptive)**

State-of-the-art set of optimization modeling tools, APIs and algorithms.

Planning and scheduling of scarce resources:

- Supply chain management
- Price optimization
- Product assortment
- Workforce planning.

Offerings:

18

- CPLEX Optimization Studio (COS)
- Decision Optimization on Cloud (DOcplexCloud)
- DSXL add-on component (DO4DSX)



## **IBM Decision Optimization**





## **Moving From Traditional Optimization to Prescriptive Analytics**



#### Example:

- 1. Predict Demand for Window Air Conditioners by Zip Code based on Weather Forecast
- 2. Optimize Quantity of Window Air Conditioners in Store to Maximize Sales
- 3. Ship x quantity to each store

#### IBM Analytics

### **DSXL Model Management and Deployment**

- Features:
- Deploy Python, R, & Spark Models online or batch
- Track model accuracy and schedule evaluations
- Load-balancing support

#### Pain Points:

- Lack of defined processes or standards for model deployment
- Handoffs from the teams responsible for development to production
- Difficult to compare and validate models value
- Value Proposition:
  - Get models into production faster
  - Keep models performing at their best
  - Securely manage the development to production workflow



### **End Uses Of Data Science**





## Data Science Experience Putting It All Together



Data Science Experience



6

## ICP4Data – More than Just DSX

	<b>ICP for Data</b> End-to-end data management, governance, & data science	<b>DSX Local</b> standalone enterprise data science
Analyze	Data Science & ML Visualization & Reports etc.	IDEs     WEX     SPSS     DO       Image: Spss     Image: Spss     Image: Spss     Image: Spss       Image: Spss     Image: Spss     Image: Spss     Image: Spss <tr< th=""></tr<>
Organize	Data Catalog Data Integration / ETL Data Quality, MDM etc.	
Collect	IBM Data Stores (e.g. Db2) Non – IBM Data Stores Federation / virtualization etc.	Customer defined

January 2018 / © 2018 IBM Corporation

23



## **Data Science Experience Local - Architecture**

25





## **Installation For DSX Local**



## **DSX Local**



27 © 2018 IBM Corporation. Author: Steven Geringer, Data Science Solutions Architect. Permission is granted to use or distribute this unmodified image, provided that this copyright remains intact.

## **DSX - Spark Architecture**





## **Crash Course on Machine Learning**



### **Machine Learning**

– Systems that learn from data using math





## **Supervised Learning**

- Most Basic Type of Machine Learning
- Known 'Target' Values
- Either:



– Regression



Source: http://ipython-books.github.io/featured-04/

- Other types of ML include:
  - Unsupervised Learning, Recommender Systems, Anomaly Detection, Reinforcement Learning, Deep Learning, Cognitive Systems

## What is an Algorithm ? – Example: Ordinary Least Squares



Source: https://bookdown.org/sbikienga/Intro\_to\_stat\_book/

### **Underfitting vs Overfitting**





## **Understanding Random Forests**



Source: https://medium.com/@williamkoehrsen/random-forest-simple-explanation-377895a60d2d

IBM. 🕉

### **Understanding Neural Networks**



#### Source: https://www.quora.com/What-is-the-difference-between-Neural-Networks-and-Deep-Learning



## **Stochastic Gradient Descent for Online (Real Time) Learning**



Fixed Size Array(s) – indexed by hash value



### **Step 1: Identify Business Objective**

- What prediction would improve your business?
  - Be Realistic, This is not Magic, it is Math !
- What data do you have? Or can you get?
- Identify Key Performance Indicator
  - Cost Reduction
  - Revenue Enhancement
  - Click Thru Rate
  - Save Lives

## **Step 2: Generate Feature Matrix From Historical Data**



## **Step 3: Training and Scoring Process**





## **Step 3: Model Scoring**

- The true test of a machine learning model is making accurate predictions on <u>unseen data.</u>
- Different Scoring Techniques for Different Problems
- Some Problems are Easier than Others
- Experiment with different techniques to improve score
  - Different ML Algorithms and Parameters
  - Different Mathematical Representations
  - Engineer New Features



## Step 4: Model Deployment: Moving your machine learning model into production



41 © 2018 IBM Corporation. Author: Steven Geringer, Data Science Solutions Architect. Permissi is granted to use on Vistribute this unmodified image, provided that this copyright remains intact.

## **To The Demo – San Francisco Fire Department**





#### Legal Disclaimer

- © IBM Corporation 2018. All Rights Reserved.
- The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on IBM's current product plans and strategy, which are subject to change by IBM without notice. IBM shall not be responsible for any damages arising out of the use of, or otherwise related to, this publication or any other materials. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from IBM or its suppliers or licensors, or altering the terms and conditions of the applicable license agreement governing the use of IBM software.
- References in this presentation to IBM products, programs, or services do not imply that they will be available in all countries in which IBM operates. Product release dates and/or capabilities referenced in this presentation may change at any time at IBM's sole discretion based on market opportunities or other factors, and are not intended to be a commitment to future product or feature availability in any way. Nothing contained in these materials is intended to, nor shall have the effect of, stating or implying that any activities undertaken by you will result in any specific sales, revenue growth or other results.
- If the text contains performance statistics or references to benchmarks, insert the following language; otherwise delete:
   Performance is based on measurements and projections using standard IBM benchmarks in a controlled environment. The actual throughput or performance that any user will
   experience will vary depending upon many factors, including considerations such as the amount of multiprogramming in the user's job stream, the I/O configuration, the storage
   configuration, and the workload processed. Therefore, no assurance can be given that an individual user will achieve results similar to those stated here.
- If the text includes any customer examples, please confirm we have prior written approval from such customer and insert the following language; otherwise delete: All customer examples described are presented as illustrations of how those customers have used IBM products and the results they may have achieved. Actual environmental costs and performance characteristics may vary by customer.
- Please review text for proper trademark attribution of IBM products. At first use, each product name must be the full name and include appropriate trademark symbols (e.g., IBM Lotus® Sametime® Unyte™). Subsequent references can drop "IBM" but should include the proper branding (e.g., Lotus Sametime Gateway, or WebSphere Application Server). Please refer to <a href="http://www.ibm.com/legal/copytrade.shtml">http://www.ibm.com/legal/copytrade.shtml</a> for guidance on which trademarks require the ® or ™ symbol. Do not use abbreviations for IBM product names in your presentation. All product names must be used as adjectives rather than nouns. Please list all of the trademarks that you use in your presentation as follows; delete any not included in your presentation. IBM, the IBM logo, Lotus, Lotus Notes, Notes, Domino, Quickr, Sametime, WebSphere, UC2, PartnerWorld and Lotusphere are trademarks of International Business Machines Corporation in the United States, other countries, or both. Unyte is a trademark of WebDialogs, Inc., in the United States, other countries, or both.
- If you reference Adobe® in the text, please mark the first use and include the following; otherwise delete: Adobe, the Adobe logo, PostScript, and the PostScript logo are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States, and/or other countries.
- If you reference Java™ in the text, please mark the first use and include the following; otherwise delete: Java and all Java-based trademarks and logos are trademarks or registered trademarks of Oracle and/or its affiliates.
- If you reference Microsoft® and/or Windows® in the text, please mark the first use and include the following, as applicable; otherwise delete: Microsoft and Windows are trademarks of Microsoft Corporation in the United States, other countries, or both.
- If you reference Intel® and/or any of the following Intel products in the text, please mark the first use and include those that you use as follows; otherwise delete: Intel, Intel Centrino, Celeron, Intel Xeon, Intel SpeedStep, Itanium, and Pentium are trademarks or registered trademarks of Intel Corporation or its subsidiaries in the United States and other countries.
- If you reference UNIX® in the text, please mark the first use and include the following; otherwise delete: UNIX is a registered trademark of The Open Group in the United States and other countries.
- If you reference Linux® in your presentation, please mark the first use and include the following; otherwise delete: Linux is a registered trademark of Linus Torvalds in the United States, other countries, or both. Other company, product, or service names may be trademarks or service marks of others.
- If the text/graphics include screenshots, no actual IBM employee names may be used (even your own), if your screenshots include fictitious company names (e.g., Renovations, Zeta Bank, Acme) please update and insert the following; otherwise delete: All references to [insert fictitious company name] refer to a fictitious company and are used for illustration purposes only.